Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010.

Buchacz K, Lau B, Jing Y, Bosch R, Abraham AG, Gill MJ, Silverberg MJ, Goedert JJ, Sterling TR, Althoff KN, Martin JN, Burkholder G, Gandhi N, Samji H, Patel P, Rachlis A, Thorne JE, Napravnik S, Henry K, Mayor A, Gebo K, Gange SJ, Moore RD, Brooks JT; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA..

J Infect Dis. 2016 Sep 15;214(6):862-72. doi: 10.1093/infdis/jiw085.

PMID:
27559122
2.

Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy.

Trickey A, May MT, Vehreschild J, Obel N, Gill MJ, Crane H, Boesecke C, Samji H, Grabar S, Cazanave C, Cavassini M, Shepherd L, d'Arminio Monforte A, Smit C, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice AC, Sterling T, Miro J, Ingle S, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC)..

PLoS One. 2016 Aug 15;11(8):e0160460. doi: 10.1371/journal.pone.0160460.

3.

Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study.

May MT, Vehreschild JJ, Trickey A, Obel N, Reiss P, Bonnet F, Mary-Krause M, Samji H, Cavassini M, Gill MJ, Shepherd LC, Crane HM, d'Arminio Monforte A, Burkholder GA, Johnson MM, Sobrino-Vegas P, Domingo P, Zangerle R, Justice AC, Sterling TR, Miró JM, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC)..

Clin Infect Dis. 2016 Jun 15;62(12):1571-7. doi: 10.1093/cid/ciw183.

4.

Monitoring of HIV treatment in seven countries in the WHO Region of the Americas.

Belaunzarán-Zamudio PF, Caro-Vega YN, Shepherd BE, Crabtree-Ramírez BE, Luz PM, Grinsztejn B, Cesar C, Cahn P, Cortés C, Wolff M, Pape JW, Padgett D, Gotuzzo E, McGowan C, Sierra-Madero JG; CCASAnet..

Bull World Health Organ. 2015 Aug 1;93(8):529-39. doi: 10.2471/BLT.14.147447.

5.

Women, Aging, and HIV: Clinical Issues and Management Strategies.

Womack JA, Brandt CA, Justice AC.

J Nurse Pract. 2014 Jun 1;10(6):409-416.

6.

Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study.

Picat MQ, Lewis J, Musiime V, Prendergast A, Nathoo K, Kekitiinwa A, Nahirya Ntege P, Gibb DM, Thiebaut R, Walker AS, Klein N, Callard R; ARROW Trial Team..

PLoS Med. 2013 Oct;10(10):e1001542. doi: 10.1371/journal.pmed.1001542.

7.

Prevalence of clinically captured and confirmed malaria among HIV seropositve clinic attendants in five hospitals in Ghana.

Adu-Gyasi D, Fanello CI, Baiden F, Porter JD, Korbel D, Adjei G, Mahama E, Manu A, Asante KP, Newton S, Owusu-Agyei S.

Malar J. 2013 Oct 30;12:382. doi: 10.1186/1475-2875-12-382.

8.

Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).

May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, D'Arminio Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe FC, Dabis F, Fätkenheuer G, Sterling TR, del Amo J, Gill MJ, Crane HM, Saag MS, Guest J, Brodt HR, Sterne JA; Antiretroviral Cohort Collaboration..

Int J Epidemiol. 2014 Jun;43(3):691-702. doi: 10.1093/ije/dyt010.

9.

The interplay between CD4 cell count, viral load suppression and duration of antiretroviral therapy on mortality in a resource-limited setting.

Brennan AT, Maskew M, Sanne I, Fox MP.

Trop Med Int Health. 2013 May;18(5):619-31. doi: 10.1111/tmi.12079.

10.

Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study.

Oliveira I, Andersen A, Furtado A, Medina C, da Silva D, da Silva ZJ, Aaby P, Laursen AL, Wejse C, Eugen-Olsen J; Bissau HIV cohort study group..

BMJ Open. 2012 Nov 14;2(6). pii: e001587. doi: 10.1136/bmjopen-2012-001587.

11.

Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort study.

Napravnik S, Eron JJ, Sterling TR, Juday T, Uy J, Moore RD.

AIDS Res Hum Retroviruses. 2013 Mar;29(3):574-80. doi: 10.1089/AID.2012.0210.

12.

Laboratory and clinical predictors of disease progression following initiation of combination therapy in HIV-infected adults in Thailand.

Duong T, Jourdain G, Ngo-Giang-Huong N, Le Cœur S, Kantipong P, Buranabanjasatean S, Leenasirimakul P, Ariyadej S, Tansuphasawasdikul S, Thongpaen S, Lallemant M; Program for HIV Prevention and Treatment Study Group..

PLoS One. 2012;7(8):e43375.

13.

Clinical, demographic and laboratory parameters at HAART initiation associated with decreased post-HAART survival in a U.S. military prospective HIV cohort.

Lifson AR, Krantz EM, Grambsch PL, Macalino GE, Crum-Cianflone NF, Ganesan A, Okulicz JF, Eaton A, Powers JH, Eberly LE, Agan BK; Infectious Disease Clinical Research Program HIV/STI Working Group..

AIDS Res Ther. 2012 Feb 10;9(1):4. doi: 10.1186/1742-6405-9-4.

14.

Long-term antiretroviral treatment outcomes in seven countries in the Caribbean.

Koenig SP, Rodriguez LA, Bartholomew C, Edwards A, Carmichael TE, Barrow G, Cabié A, Hunter R, Vasquez-Mora G, Quava-Jones A, Adomakoh N, Peter Figueroa J, Liautaud B, Torres M, Pape JW.

J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):e60-71. doi: 10.1097/QAI.0b013e318245d3c1.

15.

Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.

May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D, Palfreeman A, Gilson R, Gazzard B, Hill T, Walsh J, Fisher M, Orkin C, Ainsworth J, Bansi L, Phillips A, Leen C, Nelson M, Anderson J, Sabin C.

BMJ. 2011 Oct 11;343:d6016. doi: 10.1136/bmj.d6016.

16.

Immune status at presentation for HIV clinical care in Rio de Janeiro and Baltimore.

Moreira RI, Luz PM, Struchiner CJ, Morgado M, Veloso VG, Keruly JC, Grinsztejn B, Moore RD.

J Acquir Immune Defic Syndr. 2011 Aug;57 Suppl 3:S171-8. doi: 10.1097/QAI.0b013e31821e9d59.

17.

Epidemiological characteristics and predictors of late presentation of HIV infection in Barcelona (Spain) during the period 2001-2009.

de Olalla PG, Manzardo C, Sambeat MA, Ocaña I, Knobel H, Humet V, Domingo P, Ribera E, Guelar A, Marco A, Belza MJ, Miró JM, Caylà JA; HIV Surveillance Group..

AIDS Res Ther. 2011 Jul 6;8(1):22. doi: 10.1186/1742-6405-8-22.

18.

CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.

Li X, Margolick JB, Jamieson BD, Rinaldo CR, Phair JP, Jacobson LP.

J Acquir Immune Defic Syndr. 2011 Aug 15;57(5):421-8. doi: 10.1097/QAI.0b013e31821e9f21.

Items per page

Supplemental Content

Support Center